Dashboard
Manage Tickers

AMPH Amphastar Pharmaceuticals, ...

Nasdaq amphastar.com


$ 24.52 $ -0.20 (-0.81 %)    

Friday, 24-Oct-2025 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 24.52
$ 24.72
$ 23.96 x 65
$ 27.40 x 200
$ 24.46 - $ 24.89
$ 20.39 - $ 53.96
220,779
na
1.14B
$ 0.56
$ 8.46
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-15-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amphastar-pharmaceuticals-appoints-chengong-as-exclusive-distributor-for-baqsimi-in-greater-china-under-10-year-agreement
Amphastar Pharmaceuticals Appoints Chengon...
10/24/2025 20:28:56

On October 21, 2025 (the "Effective Date") Amphastar Pharmaceuticals, Inc. ("Amphastar"), a wholly-owned subsid...

demystifying-amphastar-pharma-insights-from-4-analyst-reviews
Demystifying Amphastar Pharma: Insights Fr...
10/22/2025 12:01:00

needham-reiterates-buy-on-amphastar-pharma-maintains-36-price-target
Needham Reiterates Buy on Amphastar Pharma...
10/22/2025 10:51:33

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) with a Buy and maintains $36 price target.

teva-viatris-on-investor-watch-as-white-house-spares-generic-drugs-from-tariffs
Teva, Viatris On Investor Watch As White H...
10/09/2025 13:31:09

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...

on-sept-15-amphastar-pharmaceuticals-enters-contract-research-agreement-with-hanxin
On Sept 15, Amphastar Pharmaceuticals Ente...
09/18/2025 20:52:31

-SEC Filing

b-of-a-securities-maintains-neutral-on-amphastar-pharma-raises-price-target-to-32
B of A Securities Maintains Neutral on Amp...
08/26/2025 15:23:26

B of A Securities analyst Jason Gerberry maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and raises the price target...

amphastar-secures-fda-nod-for-iron-sucrose-injection-analysts-eye-major-sales-momentum
Amphastar Secures FDA Nod For Iron Sucrose...
08/12/2025 17:38:58

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...

needham-upgrades-amphastar-pharma-to-buy-announces-36-price-target
Needham Upgrades Amphastar Pharma to Buy, ...
08/12/2025 12:16:47

Needham analyst Serge Belanger upgrades Amphastar Pharma (NASDAQ:AMPH) from Hold to Buy and announces $36 price target.

amphastar-pharmaceuticals-signs-453m-exclusive-licensing-deal-with-nanjing-anji-for-three-proprietary-peptides-in-oncology-and-ophthalmology
Amphastar Pharmaceuticals Signs $453M Excl...
08/12/2025 10:03:39

the-fda-approved-amphastar-pharmaceuticals-abbreviated-new-drug-application-for-iron-sucrose-injection-in-single-dose-vials-indicated-for-iron-deficiency-anemia-in-patients-with-chronic-kidney-disease
The FDA Approved Amphastar Pharmaceuticals...
08/11/2025 10:04:06

According to IQVIA, the U.S. sales for Venofer® were approximately $513 million for the 12 months ended June 30, 2025. Pipeline...

piper-sandler-maintains-neutral-on-amphastar-pharma-lowers-price-target-to-25
Piper Sandler Maintains Neutral on Amphast...
08/08/2025 11:25:43

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target fro...

amphastar-pharma-q2-adj-eps-085-beats-076-estimate-sales-174414m-beat-174249m-estimate
Amphastar Pharma Q2 Adj. EPS $0.85 Beats $...
08/07/2025 20:09:32

Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.7...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday
This Target Analyst Turns Bearish; Here Ar...
05/12/2025 13:26:47

jp-morgan-downgrades-amphastar-pharma-to-neutral-lowers-price-target-to-30
JP Morgan Downgrades Amphastar Pharma to N...
05/12/2025 12:23:03

JP Morgan analyst Ekaterina Knyazkova downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Neutral and lowers the pr...

wells-fargo-maintains-overweight-on-amphastar-pharma-lowers-price-target-to-35
Wells Fargo Maintains Overweight on Amphas...
05/08/2025 13:21:39

Wells Fargo analyst Cerena Chen maintains Amphastar Pharma (NASDAQ:AMPH) with a Overweight and lowers the price target from ...

amphastar-pharma-q1-adj-eps-074-beats-069-estimate-sales-17053m-miss-17294m-estimate
Amphastar Pharma Q1 Adj. EPS $0.74 Beats $...
05/07/2025 20:10:12

Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.6...

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

earnings-outlook-for-amphastar-pharma
Earnings Outlook For Amphastar Pharma
05/06/2025 15:04:18

needham-reiterates-hold-on-amphastar-pharmato-hold
Needham Reiterates Hold on Amphastar Pharm...
04/10/2025 11:01:10

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) from Hold to Hold.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION